Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort …
V Tahmaz, U Gehlsen, L Sauerbier, U Holtick… - British Journal of …, 2017 - bjo.bmj.com
Background/Aims To analyse patients with chronic ocular graft-versus-host disease (GvHD)
under treatment with 100% autologous serum eye drops from a sealed manufacturing …
under treatment with 100% autologous serum eye drops from a sealed manufacturing …
[引用][C] Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective …
V Tahmaz, U Gehlsen, L Sauerbier, U Holtick… - British Journal of …, 2016 - cir.nii.ac.jp
Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye
drops from a sealed manufacturing system: a retrospective cohort study | CiNii Research CiNii …
drops from a sealed manufacturing system: a retrospective cohort study | CiNii Research CiNii …
Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort …
V Tahmaz, U Gehlsen, L Sauerbier, U Holtick… - Br. J …, 2017 - kups.ub.uni-koeln.de
Background/Aims To analyse patients with chronic ocular graft-versus-host disease (GvHD)
under treatment with 100% autologous serum eye drops from a sealed manufacturing …
under treatment with 100% autologous serum eye drops from a sealed manufacturing …
Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort …
V Tahmaz, U Gehlsen, L Sauerbier… - The British journal …, 2017 - pubmed.ncbi.nlm.nih.gov
Background/aims To analyse patients with chronic ocular graft-versus-host disease (GvHD)
under treatment with 100% autologous serum eye drops from a sealed manufacturing …
under treatment with 100% autologous serum eye drops from a sealed manufacturing …
Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort …
V Tahmaz, U Gehlsen, L Sauerbier… - The British Journal of …, 2016 - europepmc.org
Methods 17 patients with chronic ocular GvHD received 100% autologous serum eye drops
from single use vials manufactured in a sealed system. Retrospective analysis included …
from single use vials manufactured in a sealed system. Retrospective analysis included …
Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort …
V Tahmaz, U Gehlsen, L Sauerbier… - British Journal of …, 2017 - search.proquest.com
Methods 17 patients with chronic ocular GvHD received 100% autologous serum eye drops
from single use vials manufactured in a sealed system. Retrospective analysis included …
from single use vials manufactured in a sealed system. Retrospective analysis included …
Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort …
V Tahmaz, U Gehlsen, L Sauerbier, U Holtick… - British Journal of …, 2016 - bjo.bmj.com
Background/Aims To analyse patients with chronic ocular graft-versus-host disease (GvHD)
under treatment with 100% autologous serum eye drops from a sealed manufacturing …
under treatment with 100% autologous serum eye drops from a sealed manufacturing …
Treatment of severe chronic ocular graft-versus-host disease using 100% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort …
V Tahmaz, U Gehlsen, L Sauerbier, U Holtick… - Br. J …, 2017 - kups.ub.uni-koeln.de
Background/Aims To analyse patients with chronic ocular graft-versus-host disease (GvHD)
under treatment with 100% autologous serum eye drops from a sealed manufacturing …
under treatment with 100% autologous serum eye drops from a sealed manufacturing …